INTERIM FINDINGS FROM GLOBAL TRIAL EXTEND POSITIVE BENEFITS OF VELCADE TO NEWLY DIAGNOSED PATIENTS
The combination therapy of VELCADE, melphalan and prednisone (VMP) demonstrates a significant advantage for patients newly diagnosed with myeloma. The therapy is already approved for use in patients who have received a previous treatment.
back
print
related articles
Be the first to comment